Literature DB >> 20544404

Increased drug efflux along with midkine gene high expression in childhood B-lineage acute lymphoblastic leukemia cells.

Ronghua Hu1, Yan Yan, Qinghua Li, Yani Lin, Weina Jin, Huawen Li, Ying Lu, Tianxiang Pang.   

Abstract

Multidrug resistance (MDR) induced by drug efflux has been identified as the major clinical obstacle in the treatment of childhood acute lymphoblastic leukemia (ALL). To explore the possible effects of midkine (MK) gene on the chemotherapeutic drugs efflux, we examined the MK gene expression in 139 B-lineage ALL patients and 15 children with nonmalignant hematological diseases. Meanwhile, we detected the degree of drug accumulation in 30 progressing B-lineage ALL patients and the 15 control individuals (as control). The results showed that the significant statistic difference in MK gene expression was found among the normal group, the complete remission (CR), and progressing B-lineage ALL patients (p < 0.01). In the Rhodamine 123 (Rh123) efflux test, mean fluorescence intensity (MFI) in the leukemia cells was obviously lower than that in normal pre-B cells (p < 0.01). Furthermore, there was an evident negative correlation between the MFI and MK mRNA expression (r = -0.869, p < 0.001) but no correlation with the MDR1 mRNA expression (p > 0.05). We concluded that there was powerful drug efflux ability in lymphoblastic leukemia cells with high MK gene expression. MK gene may take part in multidrug resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20544404     DOI: 10.1007/s12185-010-0613-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  18 in total

Review 1.  Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy.

Authors:  Ryungsa Kim; Kazuaki Tanabe; Yoko Uchida; Manabu Emi; Hideki Inoue; Tetsuya Toge
Journal:  Cancer Chemother Pharmacol       Date:  2002-10-03       Impact factor: 3.333

Review 2.  The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research.

Authors:  Michael M Gottesman; Victor Ling
Journal:  FEBS Lett       Date:  2005-12-28       Impact factor: 4.124

Review 3.  Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.

Authors:  Takashi Tsuruo; Mikihiko Naito; Akihiro Tomida; Naoya Fujita; Tetsuo Mashima; Hiroshi Sakamoto; Naomi Haga
Journal:  Cancer Sci       Date:  2003-01       Impact factor: 6.716

4.  Increased midkine gene expression in childhood B-precursor acute lymphoblastic leukemia.

Authors:  Hirokazu Hidaka; Hiroshi Yagasaki; Yoshiyuki Takahashi; Asahito Hama; Nobuhiro Nishio; Makito Tanaka; Nao Yoshida; Itzel Bustos Villalobos; Yue Wang; Yinyan Xu; Keizo Horibe; Sen Chen; Kenji Kadomatsu; Seiji Kojima
Journal:  Leuk Res       Date:  2007-01-30       Impact factor: 3.156

5.  Receptor-type protein tyrosine phosphatase zeta as a component of the signaling receptor complex for midkine-dependent survival of embryonic neurons.

Authors:  Nahoko Sakaguchi; Hisako Muramatsu; Keiko Ichihara-Tanaka; Nobuaki Maeda; Masaharu Noda; Tokuo Yamamoto; Makoto Michikawa; Shinya Ikematsu; Sadatoshi Sakuma; Takashi Muramatsu
Journal:  Neurosci Res       Date:  2003-02       Impact factor: 3.304

Review 6.  Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis.

Authors:  Takashi Muramatsu
Journal:  J Biochem       Date:  2002-09       Impact factor: 3.387

7.  Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays.

Authors:  Hio Chung Kang; Il-Jin Kim; Jae-Hyun Park; Yong Shin; Ja-Lok Ku; Mi Sun Jung; Byong Chul Yoo; Hark Kyun Kim; Jae-Gahb Park
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

8.  Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance.

Authors:  Ying Huang; Pascale Anderle; Kimberly J Bussey; Catalin Barbacioru; Uma Shankavaram; Zunyan Dai; William C Reinhold; Audrey Papp; John N Weinstein; Wolfgang Sadée
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

9.  Midkine induced growth of ameloblastoma through MAPK and Akt pathways.

Authors:  F Sandra; H Harada; N Nakamura; M Ohishi
Journal:  Oral Oncol       Date:  2004-03       Impact factor: 5.337

10.  Midkine protects hepatocellular carcinoma cells against TRAIL-mediated apoptosis through down-regulation of caspase-3 activity.

Authors:  Tomoko Ohuchida; Kohji Okamoto; Kazuhisa Akahane; Aiichiro Higure; Hidekazu Todoroki; Yukio Abe; Makoto Kikuchi; Shinya Ikematsu; Takashi Muramatsu; Hideaki Itoh
Journal:  Cancer       Date:  2004-06-01       Impact factor: 6.860

View more
  8 in total

Review 1.  Midkine as a regulator of B cell survival in health and disease.

Authors:  Sivan Cohen; Idit Shachar
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 2.  Involvement of midkine in neuroblastoma tumourigenesis.

Authors:  S Kishida; K Kadomatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

3.  Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine.

Authors:  Mine Erguven; Ayhan Bilir; Nuray Yazihan; Seval Korkmaz; Esin Aktas; Cem Ovalioglu; Tolga Dundar; Hakan Seyithanoglu
Journal:  Oncol Lett       Date:  2011-10-04       Impact factor: 2.967

Review 4.  Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.

Authors:  Panagiota S Filippou; George S Karagiannis; Anastasia Constantinidou
Journal:  Oncogene       Date:  2019-12-04       Impact factor: 9.867

5.  Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine.

Authors:  Mine Erguven; Ayhan Bilir; Nuray Yazihan; Ezgi Ermis; Akin Sabanci; Esin Aktas; Yavuz Aras; Vehbi Alpman
Journal:  Cancer Cell Int       Date:  2011-06-08       Impact factor: 5.722

6.  Clinicopathological features and prognostic value of SOX11 in childhood acute lymphoblastic leukemia.

Authors:  Toni Grönroos; Artturi Mäkinen; Saara Laukkanen; Juha Mehtonen; Atte Nikkilä; Laura Oksa; Samuli Rounioja; Yanara Marincevic-Zuniga; Jessica Nordlund; Virva Pohjolainen; Timo Paavonen; Merja Heinäniemi; Olli Lohi
Journal:  Sci Rep       Date:  2020-02-06       Impact factor: 4.379

Review 7.  Dodging the bullet: therapeutic resistance mechanisms in pediatric cancers.

Authors:  Nilay Shah
Journal:  Cancer Drug Resist       Date:  2019-09-19

8.  Effect of midkine on gemcitabine resistance in biliary tract cancer.

Authors:  Yongliang Lu; Bing Yan; Huihui Guo; Li Qiu; Xinrong Sun; Xiang Wang; Qian Shi; Ying Bao
Journal:  Int J Mol Med       Date:  2018-01-18       Impact factor: 4.101

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.